HHLR ADVISORS, LTD.
SuperinvestorHHLR Advisors (Hillhouse)
- SEC CIK
- 0001762304
- Manager
- Zhang Lei
- Style
- Growth
BBIO holding history
BridgeBio Pharma, Inc.
Every 13F filing in which HHLR Advisors (Hillhouse) reported holding BBIO, plus the quarters it sold out. Changes compare share counts with the previous calendar quarter.
BBIO overviewAll 13F holders of BBIOFull portfolio
| Quarter | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.00% | −1,023,950−100.0% | Sold out |
| Q4 2024 | 1,023,950 | $28.1M | 0.97% | 00.0% | Unchanged |
| Q3 2024 | 1,023,950 | $26.07M | 0.57% | −366,703−26.4% | Reduced |
| Q2 2024 | 1,390,653 | $35.23M | 0.87% | +23,164+1.7% | Added |
| Q1 2024 | 1,367,489 | $42.28M | 0.92% | −23,751−1.7% | Reduced |
| Q4 2023 | 1,391,240 | $56.16M | 1.13% | −1,391,510−50.0% | Reduced |
| Q3 2023 | 2,782,750 | $73.38M | 1.64% | −210,697−7.0% | Reduced |
| Q2 2023 | 2,993,447 | $51.49M | 1.10% | −984,963−24.8% | Reduced |
| Q1 2023 | 3,978,410 | $65.96M | 1.17% | −1,208,815−23.3% | Reduced |
| Q4 2022 | 5,187,225 | $39.53M | 0.83% | −174,789−3.3% | Reduced |
| Q3 2022 | 5,362,014 | $53.3M | 1.40% | 00.0% | Unchanged |
| Q2 2022 | 5,362,014 | $48.69M | 1.04% | 00.0% | Unchanged |
| Q1 2022 | 5,362,014 | $54.42M | 1.14% | 00.0% | Unchanged |
| Q4 2021 | 5,362,014 | $89.44M | 1.38% | 00.0% | Unchanged |
| Q3 2021 | 5,362,014 | $251.32M | 3.29% | 00.0% | Unchanged |
| Q2 2021 | 5,362,014 | $326.87M | 3.36% | 00.0% | Unchanged |
| Q1 2021 | 5,362,014 | $330.3M | 3.26% | +5,362,014 | New |